|
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer Clinical research trials and Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer. Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer  Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
For Condition: recurrent breast cancer,Male Breast Cancer,stage 4 breast cancer
Status: Not yet recruiting
Sponsor(s): North Central Cancer Treatment Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy, such as irinotecan and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan with docetaxel in treating patients who have refractorymetastatic breast cancer.
Details: OBJECTIVES: Primary - Determine the antitumor activity of irinotecan and docetaxel, in terms of response rate, in patients with refractory metastatic breast cancer. Secondary - Determine the toxicity profile of this regimen in these patients. - Determine the progression-free and overall survival of patients treated with this regimen. OUTLINE: This is a multicenter study. Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1.5 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR. Patients are followed every 2 months until disease progression and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study within 20 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the breast - Metastatic disease - Previously treated with chemotherapy in the adjuvant setting and/or for metastatic disease - At least one unidimensionally measurable lesion - At least 20 mm by CT scan or MRI OR at least 10 mm by spiral CT scan - Superficial clinical lesions (e.g., skin nodules or palpable lymph nodes) are allowed - Lesions on chest x-ray are allowed provided they are clearly defined and surrounded by aerated lung - The following are not considered measurable: - Bone lesions - Ascites - Leptomeningeal disease - Pleural/pericardial effusion - Inflammatory breast disease - Lymphangitis cutis/pulmonis - Cystic lesions - No known CNS metastases unless controlled by prior surgery and/or radiotherapy - Hormone receptor status: - Estrogen receptor (ER) and/or progesterone receptor (PR) status known PATIENT CHARACTERISTICS: Age - 18 and over Sex - Male or female Menopausal status - Not specified Performance status - ECOG 0-2 Life expectancy - At least 3 months Hematopoietic - Granulocyte count 1,500/mm^3 - Hemoglobin 8.0 g/dL - Platelet count 100,000/mm^3 Hepatic - Bilirubin upper limit of normal (ULN) - Meets 1 of the following criteria: - AST or ALT ULN AND alkaline phosphatase 5 times ULN - Alkaline phosphatase ULN AND AST or ALT 5 times ULN - AST or ALT 1.5 times ULN AND alkaline phosphatase 2.5 times ULN Renal - Creatinine 1.5 times ULN Cardiovascular - No myocardial infarction within the past 180 days - No congestive heart failure - No unstable angina - No clinically significant pericardial effusion or arrhythmias Other - No active, unresolved infection - No prior severe hypersensitivity reaction to docetaxel, irinotecan, or any drug formulated with polysorbate 80 - No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - No grade 1 or greater sensory or motor neuropathy - No other concurrent severe condition that would preclude study participation - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - Prior trastuzumab (Herceptin®) required for HER-2-positive patients (unless contraindicated) Chemotherapy - See Disease Characteristics - More than 21 days since prior chemotherapy - No more than 2 prior chemotherapy regimens for metastatic disease - No prior irinotecan or docetaxel for metastatic disease - Docetaxel as adjuvant therapy allowed - No other concurrent chemotherapy Endocrine therapy - Prior hormonal therapy required for patients with ER- and/or PR-positive tumors (unless contraindicated) Radiotherapy - See Disease Characteristics - At least 30 days since prior radiotherapy - No concurrent radiotherapy Surgery - See Disease Characteristics - At least 3 weeks since prior major surgery and recovered Other - More than 7 days since prior parenteral antibiotic therapy - No other concurrent experimental drugs
Total Enrollment:
Location and Contact Information:
Overall Study Official:
EdithPerez, Study Chair, Mayo Clinic
Additional Information:
Study ID Numbers: CDR0000354417; NCCTG-N0332
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00079118
Other Stage 4 Breast Cancer Studies:
1. ICI 182780 in Treating Women With Metastatic Breast Cancer
2. Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer
3. Biological Therapy in Treating Women With Stage IV Breast Cancer
4. Vinorelbine in Treating Older Women With Stage IV Breast Cancer
5. Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer
Related Studies:
Other stage 4 breast cancer Clinical Trials
Other Clinical Trials
Other Clinical Trials
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
|
|
|
|
|
|
|
|
